Recent Advances in Nanomedicine and Survivin Targeting in Brain Cancers

References

• Brain cancer (C71) . https://canceraustralia.gov.au/affected-cancer/cancer-types/brain-cancer/brain-cancer-statistics .
   Google Scholar
• Siegel RL Miller KD Jemal A . Cancer statistics, 2016 . CA Cancer J. Clin.66 ( 1 ), 7 – 30 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Agarwal S Manchanda P Vogelbaum MA Ohlfest JR Elmquist WF . Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma . Drug Metab. Disposition41 ( 1 ), 33 – 39 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Farrall AJ Wardlaw JM . Blood–brain barrier: ageing and microvascular disease – systematic review and meta-analysis . Neurobiol. Aging30 ( 3 ), 337 – 352 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Abbott NJ Ronnback L Hansson E . Astrocyte-endothelial interactions at the blood–brain barrier . Nat. Rev. Neurosci.7 ( 1 ), 41 – 53 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Abbott NJ Patabendige AaK Dolman DEM Yusof SR Begley DJ . Structure and function of the blood–brain barrier . Neurobiol. Dis.37 ( 1 ), 13 – 25 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV . The blood–brain barrier in health and chronic neurodegenerative disorders . Neuron57 ( 2 ), 178 – 201 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Saraiva C Praca C Ferreira R Santos T Ferreira L Bernardino L . Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases . J. Control. Release235 , 34 – 47 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Friedemann U . blood–brain barrier . Physiol. Rev.22 ( 2 ), 125 – 145 ( 1942 ).
   Google Scholar
• Wolburg H Lippoldt A . Tight junctions of the blood–brain barrier: development, composition and regulation . Vascul. Pharmacol.38 ( 6 ), 323 – 337 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Hagenbuch B Gao B Meier PJ . Transport of xenobiotics across the blood–brain barrier . Physiology17 ( 6 ), 231 – 234 ( 2002 ).
   Google Scholar
• Pachter JS De Vries HE Fabry Z . The blood–brain barrier and its role in immune privilege in the central nervous system . J. Neuropathol. Exp. Neurol.62 ( 6 ), 593 – 604 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Tavares MR De Menezes LR Do Nascimento DF et al. Polymeric nanoparticles assembled with microfluidics for drug delivery across the blood–brain barrier . Eur. Phy. J. Spec. Top.225 ( 4 ), 779 – 795 ( 2016 ).
   Web of Science ®Google Scholar
• Deeken JF Löscher W . The blood–brain barrier and cancer: transporters, treatment, and trojan horses . Clin. Cancer. Res.13 ( 6 ), 1663 – 1674 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Furnari FB Fenton T Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment . Genes Dev.21 ( 21 ), 2683 – 2710 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Park JK Hodges T Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme . J. Clin. Oncol.28 ( 24 ), 3838 – 3843 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tyler MA Ulasov IV Sonabend AM et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo . Gene Ther.16 ( 2 ), 262 – 278 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kim JW Auffinger B Spencer DA et al. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters . J. Transl. Med.14 ( 1 ), 134 ( 2016 ).
   PubMedGoogle Scholar
• Ahmed AU Thaci B Tobias AL et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy . J. Natl Cancer Inst.105 ( 13 ), 968 – 977 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• He H-J Wang Y Le Y et al. Surgery upregulates high mobility group box-1 and disrupts the blood–brain barrier causing cognitive dysfunction in aged rats . CNS Neurosci. Ther.18 ( 12 ), 994 – 1002 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Raliya R Saha D Chadha TS Raman B Biswas P . Non-invasive aerosol delivery and transport of gold nanoparticles to the brain . Sci. Rep.7 , 44718 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . blood–brain barrier delivery . Drug Discov. Today12 ( 1–2 ), 54 – 61 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Neuwelt EA Goldman DL Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood–brain barrier disruption: prolonged survival and preservation of cognitive function . J. Clin. Oncol.9 ( 9 ), 1580 – 1590 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Hynynen K Mcdannold N Vykhodtseva N Jolesz FA . Noninvasive MR imaging-guided focal opening of the blood–brain barrier in rabbits . Radiology220 ( 3 ), 640 – 646 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hynynen K Mcdannold N Vykhodtseva N Jolesz FA . Non-invasive opening of BBB by focused ultrasound . Acta Neurochir. Suppl.86 , 555 – 558 ( 2003 ).
   PubMedGoogle Scholar
• Fenstermaker RA Ciesielski MJ . Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma . Expert Rev. Vaccines13 ( 3 ), 377 – 385 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chakravarti A Noll E Black PM et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas . J. Clin. Oncol.20 ( 4 ), 1063 – 1068 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Yamamoto T Tanigawa N . The role of survivin as a new target of diagnosis and treatment in human cancer . Med. Electron Microsc.34 ( 4 ), 207 – 212 ( 2001 ).
   PubMedGoogle Scholar
• Waligórska-Stachura J Jankowska A Waśko R et al. Survivin – prognostic tumor biomarker in human neoplasms – review . Ginekol. Pol.83 ( 7 ), 537 – 540 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mendez G Ozpinar A Raskin J Gultekin SH Ross DA . Case comparison and literature review of glioblastoma: a tale of two tumors . Surg. Neurol. Int.5 , 121 ( 2014 ).
   PubMedGoogle Scholar
• Sun L Joh DY Al-Zaki A et al. Theranostic application of mixed gold and superparamagnetic iron oxide nanoparticle micelles in glioblastoma multiforme . J. Biomed. Nanotechnol.12 ( 2 ), 347 – 356 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Omuro A Deangelis LM . Glioblastoma and other malignant gliomas: a clinical review . JAMA310 ( 17 ), 1842 – 1850 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Stupp R Gander M Leyvraz S Newlands E . Current and future developments in the use of temozolomide for the treatment of brain tumors . Lancet Oncol.2 ( 9 ), 552 – 560 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Bent MJVD Taphoorn MJB Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971 . J. Clin. Oncol.21 ( 13 ), 2525 – 2528 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Bicker J Alves G Fortuna A Falcão A . Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review . Eur. J. Pharm. Biopharm.87 ( 3 ), 409 – 432 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Appel EA Rowland MJ Loh XJ Heywood RM Watts C Scherman OA . Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril . Chem. Commun.48 ( 79 ), 9843 – 9845 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gaillard PJ Appeldoorn CC Dorland R et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3–101) . PLoS ONE9 ( 1 ), e82331 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wohlfart S Gelperina S Kreuter J . Transport of drugs across the blood–brain barrier by nanoparticles . J. Control. Release161 ( 2 ), 264 – 273 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Brun SN Markant SL Esparza LA et al. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma . Oncogene34 ( 29 ), 3770 – 3779 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kanwar JR Sun X Punj V et al. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal . Nanomedicine8 ( 4 ), 399 – 414 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hadinoto K Sundaresan A Cheow WS . Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review . Eur. J. Pharm. Biopharm.85 ( 3 Pt A ), 427 – 443 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Jo DH Kim JH Lee TG Kim JH . Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases . Nanomed. Nanotechnol. Biol. Med.11 ( 7 ), 1603 – 1611 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kreuter J . Application of nanoparticles for the delivery of drugs to the brain . International Congress Series1277 , 85 – 94 ( 2005 ).
   Google Scholar
• De Jong WH Borm PJA . Drug delivery and nanoparticles: applications and hazards . Int. J. Nanomed.3 ( 2 ), 133 – 149 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Reijerkerk A Appeldoorn CC Rip J De Boer M Gaillard PJ . Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3–201) improves therapeutic efficacy in a model of ocular inflammation . Invest. Ophthalmol. Vis. Sci.55 ( 4 ), 2788 – 2794 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Khlebtsov N Dykman L . Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies . Chem. Soc. Rev.40 ( 3 ), 1647 – 1671 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Goel R Shah N Visaria R Paciotti GF Bischof JC . Biodistribution of TNF-α-coated gold nanoparticles in an in vivo model system . Nanomedicine4 ( 4 ), 401 – 410 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Huile G Zhi Y Shijie C et al. Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles . Nanotechnology23 ( 43 ), 435101 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lindqvist A Rip J Gaillard PJ Bjorkman S Hammarlund-Udenaes M . Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study . Mol. Pharm.10 ( 5 ), 1533 – 1541 ( 2013 ).
   PubMedGoogle Scholar
• Birngruber T Raml R Gladdines W et al. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3–101) as compared with generic Caelyx,((R))/Doxil((R))–a cerebral open flow microperfusion pilot study . J. Pharm. Sci.103 ( 7 ), 1945 – 1948 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lee DH Rotger C Appeldoorn CC et al. Glutathione PEGylated liposomal methylprednisolone (2B3–201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis . J. Neuroimmunol.274 ( 1–2 ), 96 – 101 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• James FH Daniel NS Henry MS . The use of gold nanoparticles to enhance radiotherapy in mice . Phys. Med. Biol.49 ( 18 ), N309 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wilson R Xiaojing Z Linghong G et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle . Nanotechnology20 ( 37 ), 375101 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chithrani DB Jelveh S Jalali F et al. Gold nanoparticles as radiation sensitizers in cancer therapy . Radiat. Res.173 ( 6 ), 719 – 728 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kedar U Phutane P Shidhaye S Kadam V . Advances in polymeric micelles for drug delivery and tumor targeting . Nanomedicine6 ( 6 ), 714 – 729 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kocbek P Obermajer N Cegnar M Kos J Kristl J . Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody . J. Control. Release120 ( 1 ), 18 – 26 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Allen TM Cullis PR . Drug delivery systems: entering the mainstream . Science303 ( 5665 ), 1818 – 1822 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Davis ME Chen ZG Shin DM . Nanoparticle therapeutics: an emerging treatment modality for cancer . Nat. Rev. Drug Discov.7 ( 9 ), 771 – 782 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hosseini SF Zandi M Rezaei M Farahmandghavi F . Two-step method for encapsulation of oregano essential oil in chitosan nanoparticles: preparation, characterization and in vitro release study . Carbohydr. Polym.95 ( 1 ), 50 – 56 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kamaly N Yameen B Wu J Farokhzad OC . Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release . Chem. Rev.116 ( 4 ), 2602 – 2663 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Thomas M Klibanov AM . Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells . Proc. Natl Acad. Sci. USA100 ( 16 ), 9138 – 9143 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Kanasty R Dorkin JR Vegas A Anderson D . Delivery materials for siRNA therapeutics . Nat. Mater.12 ( 11 ), 967 – 977 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wang H-X Xiong M-H Wang Y-C Zhu J Wang J . N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver . J. Control. Release166 ( 2 ), 106 – 114 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Deshpande PP Biswas S Torchilin VP . Current trends in the use of liposomes for tumor targeting . Nanomedicine8 ( 9 ), 1509 – 1528 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wahab R Siddiqui MA Saquib Q et al. ZnO nanoparticles induced oxidative stress and apoptosis in HepG2 and MCF-7 cancer cells and their antibacterial activity . Colloids Surf. B Biointerfaces117 , 267 – 276 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Johannsen M Gneveckow U Thiesen B et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution . Eur. Urol.52 ( 6 ), 1653 – 1662 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Schroeder U Sommerfeld P Ulrich S Sabel BA . Nanoparticle technology for delivery of drugs across the blood–brain barrier . J. Pharm. Sci.87 ( 11 ), 1305 – 1307 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Zhang TT Li W Meng G Wang P Liao W . Strategies for transporting nanoparticles across the blood–brain barrier . Biomater. Sci.4 ( 2 ), 219 – 229 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Dhar S Reddy EM Prabhune A Pokharkar V Shiras A Prasad BL . Cytotoxicity of sophorolipid–gellan gum–gold nanoparticle conjugates and their doxorubicin loaded derivatives towards human glioma and human glioma stem cell lines . Nanoscale3 ( 2 ), 575 – 580 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wan X Zheng X Pang X et al. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain . Oncotarget7 ( 23 ), 34038 – 34051 ( 2016 ).
   PubMedGoogle Scholar
• Gao H Yang Z Cao S et al. Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles . Nanotechnology23 ( 43 ), 435101 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rip J Chen L Hartman R et al. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood–brain barrier in rats . J. Drug Target.22 ( 5 ), 460 – 467 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rae CD Williams SR . Glutathione in the human brain: review of its roles and measurement by magnetic resonance spectroscopy . Anal. Biochem.529 , 127 – 143 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Daraee H Etemadi A Kouhi M Alimirzalu S Akbarzadeh A . Application of liposomes in medicine and drug delivery . Artif. Cells Nanomed. Biotechnol.44 ( 1 ), 381 – 391 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Rotman M Welling MM Bunschoten A et al. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease . J. Control. Release203 , 40 – 50 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Geldenhuys W Wehrung D Groshev A Hirani A Sutariya V . Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers . Pharm. Dev. Technol.20 ( 4 ), 497 – 506 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Geldenhuys W Mbimba T Bui T Harrison K Sutariya V . Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers . J. Drug Targeting19 ( 9 ), 837 – 845 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Warner DS Sheng H Batinić-Haberle I . Oxidants, antioxidants and the ischemic brain . J. Exp. Biol.207 ( 18 ), 3221 – 3231 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kannan R Kuhlenkamp JF Ookhtens M Kaplowitz N . Transport of glutathione at blood–brain barrier of the rat: inhibition by glutathione analogs and age-dependence . J. Pharmacol. Exp. Ther.263 ( 3 ), 964 – 970 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Holtman L Van Vliet EA Appeldoorn C et al. Glutathione pegylated liposomal methylprednisolone administration after the early phase of status epilepticus did not modify epileptogenesis in the rat . Epilepsy Res.108 ( 3 ), 396 – 404 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Schweingruber N Haine A Tiede K et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis . J. Immunol.187 ( 8 ), 4310 – 4318 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mallick S Choi JS . Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery . J. Nanosci. Nanotechnol.14 ( 1 ), 755 – 765 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Simpson CA Salleng KJ Cliffel DE Feldheim DL . In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles . Nanomedicine9 ( 2 ), 257 – 263 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Liu J Yu M Zhou C Yang S Ning X Zheng J . Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance . J. Am. Chem. Soc.135 ( 13 ), 4978 – 4981 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vigderman L Zubarev ER . Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules . Adv. Drug Del. Rev.65 ( 5 ), 663 – 676 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Zhou C Long M Qin Y Sun X Zheng J . Luminescent gold nanoparticles with efficient renal clearance . Angew. Chem. Int. Ed. Engl.50 ( 14 ), 3168 – 3172 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Dimitriou NM Tsekenis G Balanikas EC et al. Gold nanoparticles, radiations and the immune system: current insights into the physical mechanisms and the biological interactions of this new alliance towards cancer therapy . Pharmacol. Ther.178 , 1 – 17 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Astashkina AI Jones CF Thiagarajan G et al. Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model . Biomaterials35 ( 24 ), 6323 – 6331 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bresee J Bond CM Worthington RJ et al. Nanoscale structure–activity relationships, mode of action, and biocompatibility of gold nanoparticle antibiotics . J. Am. Chem. Soc.136 ( 14 ), 5295 – 5300 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sindhu K Rajaram A Sreeram KJ Rajaram R . Curcumin conjugated gold nanoparticle synthesis and its biocompatibility . RSC Adv.4 ( 4 ), 1808 – 1818 ( 2014 ).
   Web of Science ®Google Scholar
• Grant SA Spradling CS Grant DN et al. Assessment of the biocompatibility and stability of a gold nanoparticle collagen bioscaffold . J. Biomed. Mater. Res. A102 ( 2 ), 332 – 339 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Li N Zhao P Astruc D . Anisotropic gold nanoparticles: synthesis, properties, applications, and toxicity . Angew. Chem. Int. Ed. Engl.53 ( 7 ), 1756 – 1789 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Louis C Pluchery O World S . Gold Nanoparticles For Physics, Chemistry And Biology . Imperial College Press, distributed by World Scientific Pub. Co. , Singapore, London ( 2012 ).
   Google Scholar
• Murphy CJ Gole AM Stone JW et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging . Acc. Chem. Res.41 ( 12 ), 1721 – 1730 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Boisselier E Astruc D . Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity . Chem. Soc. Rev.38 ( 6 ), 1759 – 1782 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Alkilany AM Murphy CJ . Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?J. Nanopart. Res.12 ( 7 ), 2313 – 2333 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Chen YS Hung YC Liau I Huang GS . Assessment of the In vivo toxicity of gold nanoparticles . Nanoscale Res. Lett.4 ( 8 ), 858 – 864 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Pannuti A Foreman K Rizzo P et al. Targeting notch to target cancer stem cells . Clin. Cancer. Res.16 ( 12 ), 3141 – 3152 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Merlos-Suárez A Barriga Francisco M Jung P et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse . Cell Stem Cell8 ( 5 ), 511 – 524 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bao S Wu Q Mclendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response . Nature444 ( 7120 ), 756 – 760 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Leder K Pitter K Laplant Q et al. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules . Cell156 ( 3 ), 603 – 616 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ache BW Young JM . Olfaction: diverse species, conserved principles . Neuron48 ( 3 ), 417 – 430 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hildebrand JG Shepherd GM . Mechanisms of olfactory discrimination: converging evidence for common principles across phyla . Annu. Rev. Neurosci.20 , 595 – 631 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Kaupp UB . Olfactory signalling in vertebrates and insects: differences and commonalities . Nat. Rev. Neurosci.11 ( 3 ), 188 – 200 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Vosshall LB Stocker RF . Molecular architecture of smell and taste in Drosophila . Annu. Rev. Neurosci.30 , 505 – 533 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Stopfer M . Olfactory processing: massive convergence onto sparse codes . Curr. Biol.17 ( 10 ), R363 – R364 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Wehr M Laurent G . Relationship between afferent and central temporal patterns in the locust olfactory system . J. Neurosci.19 ( 1 ), 381 – 390 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Boeckh J Ernst KD Selsam P . Neurophysiology and neuroanatomy of the olfactory pathway in the cockroach . Ann. NY Acad. Sci.510 , 39 – 43 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Watanabe H Nishino H Nishikawa M Mizunami M Yokohari F . Complete mapping of glomeruli based on sensory nerve branching pattern in the primary olfactory center of the cockroach Periplaneta americana . J. Comp. Neurol.518 ( 19 ), 3907 – 3930 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Huart C Rombaux P Hummel T . Plasticity of the human olfactory system: the olfactory bulb . Molecules18 ( 9 ), 11586 – 11600 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Liss L Gomez F . The nature of senile changes of the human olfactory bulb and tract . AMA Arch. Otolaryngol.67 ( 2 ), 167 – 171 ( 1958 ).
   PubMedGoogle Scholar
• Doty RL . Handbook Of Olfaction And Gustation . Wiley , Blackwell, Hoboken ( 2015 ).
   Google Scholar
• Van Riel D Verdijk R Kuiken T . The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system . J. Pathol.235 ( 2 ), 277 – 287 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shevtsov MA Nikolaev BP Ryzhov VA et al. Ionizing radiation improves glioma-specific targeting of superparamagnetic iron oxide nanoparticles conjugated with cmHsp70.1 monoclonal antibodies (SPION-cmHsp70.1) . Nanoscale7 ( 48 ), 20652 – 20664 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shevtsov MA Nikolaev BP Yakovleva LY et al. Recombinant interleukin-1 receptor antagonist conjugated to superparamagnetic iron oxide nanoparticles for theranostic targeting of experimental glioblastoma . Neoplasia17 ( 1 ), 32 – 42 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shevtsov MA Yakovleva LY Nikolaev BP et al. Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma . Neuro Oncol.16 ( 1 ), 38 – 49 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kievit FM Stephen ZR Veiseh O et al. Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs . ACS Nano6 ( 3 ), 2591 – 2601 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ma X Gong A Chen B et al. Exploring a new SPION-based MRI contrast agent with excellent water-dispersibility, high specificity to cancer cells and strong MR imaging efficacy . Colloids Surf. B Biointerfaces126 , 44 – 49 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mahajan S Koul V Choudhary V Shishodia G Bharti AC . Preparation and in vitro evaluation of folate-receptor-targeted SPION-polymer micelle hybrids for MRI contrast enhancement in cancer imaging . Nanotechnology24 ( 1 ), 015603 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gahramanov S Muldoon LL Varallyay CG et al. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival . Radiology266 ( 3 ), 842 – 852 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gahramanov S Varallyay C Tyson RM et al. Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival . CNS Oncol.3 ( 6 ), 389 – 400 ( 2014 ).
   PubMedGoogle Scholar
• Liu H Zhang J Chen X et al. Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside . Nanoscale8 ( 15 ), 7808 – 7826 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Espinosa A Di Corato R Kolosnjaj-Tabi J Flaud P Pellegrino T Wilhelm C . Duality of iron oxide nanoparticles in cancer therapy: amplification of heating efficiency by magnetic hyperthermia and photothermal bimodal treatment . ACS Nano10 ( 2 ), 2436 – 2446 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Martinez-Boubeta C Simeonidis K Makridis A et al. Learning from nature to improve the heat generation of iron-oxide nanoparticles for magnetic hyperthermia applications . Sci. Rep.3 , 1652 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pankhurst QA Thanh NTK Jones SK Dobson J . Progress in applications of magnetic nanoparticles in biomedicine . J. Phys. D-Appli. Phys.42 ( 22 ), 1 – 15 ( 2009 ).
   Google Scholar
• Munnier E Cohen-Jonathan S Linassier C et al. Novel method of doxorubicin–SPION reversible association for magnetic drug targeting . Int. J. Pharm.363 ( 1 ), 170 – 176 ( 2008 ).
   PubMedGoogle Scholar
• Ling Y Wei K Zou F Zhong S . Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma . Int. J. Pharm.430 ( 1–2 ), 266 – 275 ( 2012 ).
   PubMedGoogle Scholar
• Fang J-H Lai Y-H Chiu T-L Chen Y-Y Hu S-H Chen S-Y . Magnetic core–shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas . Adv. Healthcare Mater.3 ( 8 ), 1250 – 1260 ( 2014 ).
   Web of Science ®Google Scholar
• Cui Y Xu Q Chow PK-H Wang D Wang C-H . Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment . Biomaterials34 ( 33 ), 8511 – 8520 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Muthiah M Park I-K Cho C-S . Surface modification of iron oxide nanoparticles by biocompatible polymers for tissue imaging and targeting . Biotechnol. Adv.31 ( 8 ), 1224 – 1236 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rosen JE Chan L Shieh D-B Gu FX . Iron oxide nanoparticles for targeted cancer imaging and diagnostics . Nanomed. Nanotechnol. Biol. Med.8 ( 3 ), 275 – 290 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dosa E Guillaume DJ Haluska M et al. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol . Neuro Oncol.13 ( 2 ), 251 – 260 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Varallyay CG Muldoon LL Gahramanov S et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model . J. Cereb. Blood Flow Metab.29 ( 4 ), 853 – 860 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gkagkanasiou M Ploussi A Gazouli M Efstathopoulos EP . USPIO-enhanced MRI neuroimaging: a review . J. Neuroimaging26 ( 2 ), 161 – 168 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hygino Da Cruz LC Rodriguez I Domingues RC Gasparetto EL Sorensen AG . Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma . Am. J. Neuroradiol.32 ( 11 ), 1978 – 1985 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Brandsma D Stalpers L Taal W Sminia P Van Den Bent MJ . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas . Lancet Oncol.9 ( 5 ), 453 – 461 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Shevtsov MA Nikolaev BP Yakovleva LY et al. Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors . Int. J. Nanomedicine9 , 273 – 287 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Laurent S Dutz S Häfeli UO Mahmoudi M . Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles . Adv. Colloid Interface Sci.166 ( 1 ), 8 – 23 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Huang S-H Juang R-S . Biochemical and biomedical applications of multifunctional magnetic nanoparticles: a review . J. Nanopart. Res.13 ( 10 ), 4411 ( 2011 ).
   Web of Science ®Google Scholar
• Shahbazi-Gahrouei D Abdolahi M . Superparamagnetic iron oxide-C595: potential MR imaging contrast agents for ovarian cancer detection . J. Med. Phys.38 ( 4 ), 198 – 204 ( 2013 ).
   PubMedGoogle Scholar
• Shahbazi-Gahrouei D Abdolahi A . Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging . Sci. World J.2013 , 1 – 7 ( 2013 ).
   Google Scholar
• Long L Wang W Cai XD Cheng D Shuai X Peng Y . PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growth . Exp. Ther. Med.7 ( 5 ), 1170 – 1176 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Germer K Leonard M Zhang X . RNA aptamers and their therapeutic and diagnostic applications . Int. J. Biochem. Mol. Biol.4 ( 1 ), 27 – 40 ( 2013 ).
   PubMedGoogle Scholar
• Yin PT Shah BP Lee K-B . Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells . Small10 ( 20 ), 4106 – 4112 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gultepe E Reynoso FJ Jhaveri A et al. Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution . Nanomedicine5 ( 8 ), 1173 – 1182 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zintchenko A Philipp A Dehshahri A Wagner E . Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity . Bioconj. Chem.19 ( 7 ), 1448 – 1455 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lai XF Shen CX Wen Z et al. PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells . J. Exp. Clin. Cancer Res.31 , 12 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Elmore S . Apoptosis: a review of programmed cell death . Toxicol. Pathol.35 ( 4 ), 495 – 516 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Luo JC Shin VY Liu ESL et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs . Eur. J. Pharmacol.485 ( 1 ), 275 – 281 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wedam SB Low JA Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer . J. Clin. Oncol.24 ( 5 ), 769 – 777 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Maenosono S Saita S . Theoretical assessment of FePt nanoparticles as heating elements for magnetic hyperthermia . IEEE Trans. Magn.42 ( 6 ), 1638 – 1642 ( 2006 ).
   Web of Science ®Google Scholar
• Verma J Lal S Van Noorden CJF . Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma . Int. J. Nanomed.9 , 2863 – 2877 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Silva AC Oliveira TR Mamani JB et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment . Int. J. Nanomed.6 , 591 – 603 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Moroz P Jones SK Gray BN . The effect of tumor size on ferromagnetic embolization hyperthermia in a rabbit liver tumor model . Int. J. Hyperthermia18 ( 2 ), 129 – 140 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Ito A Shinkai M Honda H et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles . Cancer Immunol. Immunother.52 ( 2 ), 80 – 88 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ito A Shinkai M Honda H Kobayashi T . Medical application of functionalized magnetic nanoparticles . J. Biosci. Bioeng.100 ( 1 ), 1 – 11 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Dan M Bae Y Pittman TA Yokel RA . Alternating magnetic field-induced hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood–brain barrier models . Pharm. Res.32 ( 5 ), 1615 – 1625 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shinkai M Yanase M Honda H Wakabayashi T Yoshida J Kobayashi T . Intracellular hyperthermia for cancer using magnetite cationic liposomes: In vitro study . Jap. J. Cancer Res.87 ( 11 ), 1179 – 1183 ( 1996 ).
   PubMedGoogle Scholar
• Yanase M Shinkai M Honda H Wakabayashi T Yoshida J Kobayashi T . Intracellular hyperthermia for cancer using magnetite cationic liposomes: ex vivo study . Jap. J. Cancer Res.88 ( 7 ), 630 – 632 ( 1997 ).
   PubMedGoogle Scholar
• Yanase M Shinkai M Honda H Wakabayashi T Yoshida J Kobayashi T . Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study . Jap. J. Cancer Res.89 ( 4 ), 463 – 470 ( 1998 ).
   PubMedGoogle Scholar
• Yanase M Shinkai M Honda H Wakabayashi T Yoshida J Kobayashi T . Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes . Jap. J. Cancer Res.89 ( 7 ), 775 – 782 ( 1998 ).
   PubMedGoogle Scholar
• Shinkai M Yanase M Suzuki M et al. Intracellular hyperthermia for cancer using magnetite cationic liposomes . J. Magn. Magn. Mater.194 ( 1 ), 176 – 184 ( 1999 ).
   Web of Science ®Google Scholar
• Ohno T Wakabayashi T Takemura A et al. Effective solitary hyperthermia treatment of malignant glioma using stick type CMC-magnetite. In vivo study . J. Neurooncol.56 ( 3 ), 233 – 239 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Murakami N Kühnel A Schmid TE et al. Role of membrane Hsp70 in radiation sensitivity of tumor cells . Rad. Oncol.10 ( 1 ), 149 ( 2015 ).
   PubMedGoogle Scholar
• Multhoff G . Activation of natural killer cells by heat shock protein 70 . Int. J. Hyperthermia25 ( 3 ), 169 – 175 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gaca S Reichert S Multhoff G et al. Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells . J. Control. Release172 ( 1 ), 201 – 206 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Galluzzi L Giordanetto F Kroemer G . Targeting HSP70 for cancer therapy . Mol. Cell36 ( 2 ), 176 – 177 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Erlichman C . Tanespimycin: the opportunities and challenges of targeting heat shock protein 90 . Expert Opin. Invest. Drugs18 ( 6 ), 861 – 868 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K Rothe R Scholz R et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme . J. Neurooncol.81 ( 1 ), 53 – 60 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Van Landeghem FKH Maier-Hauff K Jordan A et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles . Biomaterials30 ( 1 ), 52 – 57 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K Ulrich F Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme . J. Neurooncol.103 ( 2 ), 317 – 324 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Adkins JN Varnum SM Auberry KJ et al. Toward a human blood serum proteome - Analysis by multidimensional separation coupled with mass spectrometry . Mol. Cell. Proteomics1 ( 12 ), 947 – 955 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Doweiko JP Nompleggi DJ . Role of albumin in human physiology and pathophysiology . Jpen. Parenter. Enter.15 ( 2 ), 207 – 211 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Don BR Kaysen G . Poor nutritional status and inflammation: serum albumin: relationship to inflammation and nutrition . Semin. Dial.17 ( 6 ), 432 – 437 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Vaupel P Kallinowski F Okunieff P . Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors - a Review . Cancer Res.49 ( 23 ), 6449 – 6465 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Elzoghby AO Samy WM Elgindy NA . Albumin-based nanoparticles as potential controlled release drug delivery systems . J. Control. Release157 ( 2 ), 168 – 182 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Tiruppathi C Song W Bergenfeldt M Sass P Malik AB . Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway . J. Biol. Chem.272 ( 41 ), 25968 – 25975 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Kim TH Jiang HH Youn YS et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity . Int. J. Pharm.403 ( 1 ), 285 – 291 ( 2011 ).
   PubMedGoogle Scholar
• Aoki T Nomura R Fujimoto T . Tyrosine phosphorylation of caveolin-1 in the endothelium . Exp. Cell Res.253 ( 2 ), 629 – 636 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• John TA Vogel SM Tiruppathi C Malik AB Minshall RD . Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer . Am. J. Physiol. Lung Cell. Mol. Physiol.284 ( 1 ), L187 – L196 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Liu LB Pilch PF . A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization . J. Biol. Chem.283 ( 7 ), 4314 – 4322 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Schubert W Frank PG Razani B Park DS Chow CW Lisanti MP . Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo . J. Biol. Chem.276 ( 52 ), 48619 – 48622 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Desai N Trieu V Damascelli B Soon-Shiong P . SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients . Transl. Oncol.2 ( 2 ), 59 – 64 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Dreis S Rothweiler F Michaelis M Cinatl J Jr Kreuter J Langer K . Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles . Int. J. Pharm.341 ( 1–2 ), 207 – 214 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ulbrich K Michaelis M Rothweiler F et al. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumor cells . Int. J. Pharm.406 ( 1–2 ), 128 – 134 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• He Q Guo S Qian Z Chen X . Development of individualized anti-metastasis strategies by engineering nanomedicines . Chem. Soc. Rev.44 ( 17 ), 6258 – 6286 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Siena S Sartore-Bianchi A Di Nicolantonio F Balfour J Bardelli A . Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer . J. Natl Cancer Inst.101 ( 19 ), 1308 – 1324 ( 2009 ).
   PubMedGoogle Scholar
• Lee B-C Lee T-H Avraham S Avraham HK . Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells11NIH grant NS39558 (S. Avraham), the Susan G. Komen Fellowship (S. Avraham), the Milheim Foundation (S. Avraham), CA97153 (H. Avraham), and K18 PAR-02–069 (H. Avraham). Note: This work was done during the term of an established investigatorship from the American Heart Association (H. Avraham). This article is dedicated to Charlene Engelhard for her continuing friendship and support for our research program . Mol. Cancer Res.2 ( 6 ), 327 – 338 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Altieri DC . Survivin, versatile modulation of cell division and apoptosis in cancer . Oncogene22 ( 53 ), 8581 – 8589 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Baratchi S Kanwar RK Kanwar JR . Survivin: a target from brain cancer to neurodegenerative disease . Crit. Rev. Biochem. Mol. Biol.45 ( 6 ), 535 – 554 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Altieri Dario C . Survivin and IAP proteins in cell-death mechanisms . Biochem. J.430 ( 2 ), 199 – 205 ( 2010 ).
   PubMedGoogle Scholar
• Altieri DC . Survivin – The inconvenient IAP . Semin. Cell Dev. Biol.39 , 91 – 96 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Baratchi S Kanwar RK Cheung CH Kanwar JR . Proliferative and protective effects of SurR9-C84A on differentiated neural cells . J. Neuroimmunol.227 ( 1–2 ), 120 – 132 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Carmena M Wheelock M Funabiki H Earnshaw WC . The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis . Nat. Rev. Mol. Cell Biol.13 ( 12 ), 789 – 803 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lens SMA Vader G Medema RH . The case for survivin as mitotic regulator . Curr. Opin. Cell Biol.18 ( 6 ), 616 – 622 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Sacristan C Kops GJPL . Joined at the hip: kinetochores, microtubules, and spindle assembly checkpoint signaling . Trends Cell Biol.25 ( 1 ), 21 – 28 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Vader G Kauw JJ Medema RH Lens SM . Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody . EMBO reports7 ( 1 ), 85 – 92 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lara-Gonzalez P Westhorpe Frederick G Taylor Stephen S . The spindle assembly checkpoint . Curr. Biol.22 ( 22 ), R966 – R980 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vagnarelli P Earnshaw WC . Chromosomal passengers: the four-dimensional regulation of mitotic events . Chromosoma113 ( 5 ), 211 – 222 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Salvesen GS Duckett CS . IAP proteins: blocking the road to death's door . Nat. Rev. Mol. Cell Biol.3 ( 6 ), 401 – 410 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Ciesielski MJ Kozbor D Castanaro CA Barone TA Fenstermaker RA . Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma . Cancer Immunol. Immunother.57 ( 12 ), 1827 – 1835 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Altieri DC . Validating survivin as a cancer therapeutic target . Nat. Rev. Cancer3 ( 1 ), 46 – 54 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Das A Tan W-L Teo J Smith DR . Expression of survivin in primary glioblastomas . J. Cancer Res. Clin. Oncol.128 ( 6 ), 302 – 306 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Fenstermaker RA Ciesielski MJ Qiu J et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma . Cancer Immunol. Immunother.65 ( 11 ), 1339 – 1352 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Shirai K Suzuki Y Oka K et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma . J. Neurooncol.91 ( 3 ), 353 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Stobiecka M Chalupa A Dworakowska B . Piezometric biosensors for anti-apoptotic protein survivin based on buried positive-potential barrier and immobilized monoclonal antibodies . Biosensors Bioelectron.84 ( Suppl. C ), 37 – 43 ( 2016 ).
   PubMedGoogle Scholar
• Xylinas E Kluth LA Rieken M Karakiewicz PI Lotan Y Shariat SF . Urine markers for detection and surveillance of bladder cancer . Urol. Oncol.32 ( 3 ), 222 – 229 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sarvagalla S Cheung CHA Tsai J-Y Hsieh HP Coumar MS . Disruption of protein–protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target - survivin . RSC Adv.6 ( 38 ), 31947 – 31959 ( 2016 ).
   Web of Science ®Google Scholar
• Stobiecka M Dworakowska B Jakiela S Lukasiak A Chalupa A Zembrzycki K . Sensing of survivin mRNA in malignant astrocytes using graphene oxide nanocarrier-supported oligonucleotide molecular beacons . Sensors Actuators B Chem.235 ( Suppl. C ), 136 – 145 ( 2016 ).
   Google Scholar
• Ciesielski MJ Ahluwalia MS Munich SA et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic . Cancer Immunol. Immunother.59 ( 8 ), 1211 – 1221 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ohtake J Ohkuri T Togashi Y Kitamura H Okuno K Nishimura T . Identification of novel helper epitope peptides of survivin cancer-associated antigen applicable to developing helper/killer–hybrid epitope long peptide cancer vaccine . Immunol. Lett.161 ( 1 ), 20 – 30 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Grossman SA Ye X Peereboom D et al. Phase I study of terameprocol in patients with recurrent high-grade glioma . Neuro Oncol.14 ( 4 ), 511 – 517 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Guvenc H Pavlyukov MS Joshi K et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex . Clin. Cancer. Res.19 ( 3 ), 631 – 642 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sriramoju B Kanwar RK Kanwar JR . Nanoformulated cell-penetrating survivin mutant and its dual actions . Int. J. Nanomedicine9 , 3279 – 3298 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Guo H Wang Y Song T et al. Silencing of survivin using YM155 inhibits invasion and suppresses proliferation in glioma cells . Cell Biochem. Biophys.71 ( 2 ), 587 – 593 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lai PC Chen SH Yang SH Cheng CC Chiu TH Huang YT . Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity . Pediatr. Neonatol.53 ( 3 ), 199 – 204 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Jane EP Premkumar DR Sutera PA Cavaleri JM Pollack IF . Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines . Mol. Carcinog.56 ( 4 ), 1251 – 1265 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Marino S Ricci B Greco A Acquati S . A novel polycomb feed forward loop in glioblastoma multiforme . Neuro Oncol.16 ( Suppl. 3 ), iii17 ( 2014 ).
   Google Scholar
• Peery RC Liu JY Zhang JT . Targeting survivin for therapeutic discovery: past, present, and future promises . Drug Discov. Today22 ( 10 ), 1466 – 1477 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Shamsabadi FT Eidgahi MR Mehrbod P et al. Survivin, a promising gene for targeted cancer treatment . Asian Pac. J. Cancer Prev.17 ( 8 ), 3711 – 3719 ( 2016 ).
   PubMedGoogle Scholar
• Chen X Duan N Zhang C Zhang W . Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies . J. Cancer7 ( 3 ), 314 – 323 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Altieri DC . Survivin, cancer networks and pathway-directed drug discovery . Nat. Rev. Cancer8 ( 1 ), 61 – 70 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lacasse EC Mahoney DJ Cheung HH Plenchette S Baird S Korneluk RG . IAP-targeted therapies for cancer . Oncogene27 ( 48 ), 6252 – 6275 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kelly RJ Thomas A Rajan A et al. A Phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer . Ann. Oncol.24 ( 10 ), 2601 – 2606 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yamauchi T Nakamura N Hiramoto M et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54nrb complex, which is required for survivin expression . Biochem. Biophys. Res. Commun.425 ( 4 ), 711 – 716 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rees MG Seashore-Ludlow B Cheah JH et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action . Nat. Chem. Biol.12 ( 2 ), 109 – 116 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Giaccone G Zatloukal P Roubec J et al. Multicenter Phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer . J. Clin. Oncol.27 ( 27 ), 4481 – 4486 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lewis KD Samlowski W Ward J et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma . Invest. New Drugs29 ( 1 ), 161 – 166 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cheson BD Bartlett NL Vose JM et al. A Phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma . Cancer118 ( 12 ), 3128 – 3134 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Glaros TG Stockwin LH Mullendore ME Smith B Morrison BL Newton DL . The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response . Cancer Chemother. Pharmacol.70 ( 1 ), 207 – 212 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Winter GE Radic B Mayor-Ruiz C et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity . Nat. Chem. Biol.10 ( 9 ), 768 – 773 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cheng Q Ling X Haller A et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter . Int. J. Biochem. Mol. Biol.3 ( 2 ), 179 – 197 ( 2012 ).
   PubMedGoogle Scholar
• Barth N Langmann T Schölmerich J Schmitz G Schäffler A . Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-α as regulatory pathways . Diabetologia45 ( 10 ), 1425 – 1433 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Li S Wang Q Qiang Q et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor . J. Cancer Res. Clin. Oncol.141 ( 11 ), 1909 – 1920 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pardali K Kurisaki A Moren A Ten Dijke P Kardassis D Moustakas A . Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta . J. Biol. Chem.275 ( 38 ), 29244 – 29256 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Castro-Gamero AM Borges KS Moreno DA et al. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells . Invest. New Drugs31 ( 4 ), 858 – 870 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Church DN Talbot DC . Survivin in solid tumors: rationale for development of inhibitors . Curr. Oncol. Rep.14 ( 2 ), 120 – 128 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Smolewski P . Terameprocol, a novel site-specific transcription inhibitor with anticancer activity . IDrugs11 ( 3 ), 204 – 214 ( 2008 ).
   PubMedGoogle Scholar
• Batrakova EV Gendelman HE Kabanov AV . Cell-mediated drug delivery . Expert Opin. Drug Deliv.8 ( 4 ), 415 – 433 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Xue J Zhao Z Zhang L et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence . Nat. Nanotechnol.12 ( 7 ), 692 – 700 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Baratchi S Kanwar RK Kanwar JR . Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress . PLoS ONE6 ( 1 ), e15865 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cheung CH Sun X Kanwar JR Bai JZ Cheng L Krissansen GW . A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy . Cancer Cell Int.10 , 36 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kanwar JR Kamalapuram SK Kanwar RK . Survivin signaling in clinical oncology: a multifaceted dragon . Med. Res. Rev.33 ( 4 ), 765 – 789 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Roy K Kanwar RK Krishnakumar S Cheung CHA Kanwar JR . Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model . Int. J. Nanomed.10 , 1019 – 1043 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Samarasinghe RM Gibbons J Kanwar RK Kanwar JR . Nanotechnology based platforms for survivin targeted drug discovery . Expert Opin. Drug Discov.7 ( 11 ), 1083 – 1092 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bhasker S Kislay R Rupinder KK Jagat KR . Evaluation of nanoformulated therapeutics in an ex-vivo bovine corneal irritation model . Toxicol. In vitro29 ( 5 ), 917 – 925 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Sriramoju B Kanwar RK Kanwar JR . Nanoformulated mutant SurR9-C84A: a possible key for Alzheimer's and its associated inflammation . Pharm. Res.32 ( 8 ), 2787 – 2797 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Garg H Suri P Gupta JC Talwar GP Dubey S . Survivin: a unique target for tumor therapy . Cancer Cell Int.16 ( 1 ), 49 ( 2016 ).
   PubMedGoogle Scholar
• Monaco JJ . A molecular model of MHC class-I-restricted antigen processing . Immunol. Today13 ( 5 ), 173 – 179 ( 1992 ).
   PubMedGoogle Scholar
• Germain RN . MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation . Cell76 ( 2 ), 287 – 299 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Nagaraj S Pisarev V Kinarsky L et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors . J. Immunother.30 ( 2 ), 169 – 179 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Rech AJ Vonderheide RH . Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells . Ann. NY Acad. Sci.1174 ( 1 ), 99 – 106 ( 2009 ).
   PubMedGoogle Scholar
• Hirohashi Y Torigoe T Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin . Clin. Cancer. Res.8 ( 6 ), 1731 – 1739 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Rohayem J Diestelkoetter P Weigle B et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients . Cancer Res.60 ( 7 ), 1815 – 1817 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Widenmeyer M Griesemann H Stevanović S et al. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients . Int. J. Cancer131 ( 1 ), 140 – 149 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hills T Jakeman PG Carlisle RC Klenerman P Seymour LW Cawood R . A rapid-response humoral vaccine platform exploiting pre-existing non-cognate populations of anti-vaccine or anti-viral CD4+ T helper cells to confirm B cell activation . PLoS ONE11 ( 11 ), e0166383 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Zhao PW Shi X Li C et al. IL-33 enhances humoral immunity against chronic HBV infection through activating CD4(+)CXCR5(+) TFH cells . J. Interferon Cytokine Res.35 ( 6 ), 454 – 463 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Dienz O Eaton SM Bond JP et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells . J. Exp. Med.206 ( 1 ), 69 – 78 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ryan BM O'donovan N Duffy MJ . Survivin: a new target for anti-cancer therapy . Cancer Treat. Rev.35 ( 7 ), 553 – 562 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Belardelli F . Role of interferons and other cytokines in the regulation of the immune response . APMIS103 ( 1–6 ), 161 – 179 ( 1995 ).
   PubMedGoogle Scholar
• Azmi AS Bao B Sarkar FH . Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review . Cancer Metastasis Rev.32 ( 3 ), 623 – 642 ( 2013 ).
   PubMed Web of Science ®Google Scholar